IN2014DN00145A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN00145A IN2014DN00145A IN145DEN2014A IN2014DN00145A IN 2014DN00145 A IN2014DN00145 A IN 2014DN00145A IN 145DEN2014 A IN145DEN2014 A IN 145DEN2014A IN 2014DN00145 A IN2014DN00145 A IN 2014DN00145A
- Authority
- IN
- India
- Prior art keywords
- solid forms
- amide
- pharmaceutical compositions
- present
- relates
- Prior art date
Links
- 239000007787 solid Substances 0.000 abstract 4
- 150000001408 amides Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 abstract 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 1
- -1 dimethyl ethyl Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161499222P | 2011-06-21 | 2011-06-21 | |
| PCT/EP2012/061756 WO2012175522A1 (en) | 2011-06-21 | 2012-06-19 | Polymorphs of (s)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN00145A true IN2014DN00145A (enExample) | 2015-05-22 |
Family
ID=46319784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN145DEN2014 IN2014DN00145A (enExample) | 2011-06-21 | 2012-06-19 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9006270B2 (enExample) |
| EP (1) | EP2723733A1 (enExample) |
| JP (1) | JP2014517049A (enExample) |
| KR (1) | KR20140033432A (enExample) |
| CN (1) | CN103619840B (enExample) |
| BR (1) | BR112013032687A2 (enExample) |
| CA (1) | CA2839621A1 (enExample) |
| IN (1) | IN2014DN00145A (enExample) |
| MX (1) | MX2013014887A (enExample) |
| RU (1) | RU2014101626A (enExample) |
| WO (1) | WO2012175522A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY192644A (en) | 2009-11-27 | 2022-08-29 | Genzyme Corp | An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
| CN104244949A (zh) * | 2012-03-30 | 2014-12-24 | 诺华股份有限公司 | 用于治疗神经母细胞瘤、尤文氏肉瘤或横纹肌肉瘤的化合物 |
| DK3076969T3 (da) * | 2013-12-06 | 2021-11-22 | Novartis Ag | Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer |
| EP3200772B1 (en) * | 2014-10-03 | 2022-08-03 | Novartis AG | Pharmaceutical compositions comprising alpelisib |
| EP3956330A4 (en) | 2019-04-18 | 2023-01-18 | The Johns Hopkins University | SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND THEIR USE |
| CN112961090A (zh) * | 2019-12-13 | 2021-06-15 | 武汉九州钰民医药科技有限公司 | 合成Alpelisib的关键中间体及其制备方法 |
| CN110964005A (zh) * | 2019-12-16 | 2020-04-07 | 武汉九州钰民医药科技有限公司 | 一种Alpelisib的制备工艺 |
| CN111057051A (zh) * | 2019-12-16 | 2020-04-24 | 武汉九州钰民医药科技有限公司 | PI3K抑制剂Alpelisib的新合成方法 |
| JP7649637B2 (ja) | 2020-10-06 | 2025-03-21 | エルジー ディスプレイ カンパニー リミテッド | 伝送装置及び表示システム |
| IL301817A (en) | 2020-10-13 | 2023-06-01 | Univ Johns Hopkins | Modified 4-([4,2,1]triazolo[5,1-a]pyridin-6-yl)thiophene-2-carboxamide histories and their use |
| WO2022234408A1 (en) * | 2021-05-03 | 2022-11-10 | Novartis Ag | Alpelisib formulation |
| CN116925023B (zh) * | 2023-07-18 | 2025-11-21 | 江苏桐孚高新材料有限公司 | 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY29149A1 (es) * | 2004-10-07 | 2006-05-31 | Boehringer Ingelheim Int | Tiazolil-dihidro-indazoles |
| JP2009535386A (ja) * | 2006-05-03 | 2009-10-01 | アストラゼネカ アクチボラグ | チアゾール誘導体および抗腫瘍剤としてのその使用 |
| UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| AR082418A1 (es) * | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
-
2012
- 2012-06-19 JP JP2014516316A patent/JP2014517049A/ja active Pending
- 2012-06-19 MX MX2013014887A patent/MX2013014887A/es not_active Application Discontinuation
- 2012-06-19 CN CN201280030432.6A patent/CN103619840B/zh not_active Expired - Fee Related
- 2012-06-19 IN IN145DEN2014 patent/IN2014DN00145A/en unknown
- 2012-06-19 KR KR1020137033590A patent/KR20140033432A/ko not_active Withdrawn
- 2012-06-19 WO PCT/EP2012/061756 patent/WO2012175522A1/en not_active Ceased
- 2012-06-19 EP EP12728285.3A patent/EP2723733A1/en not_active Withdrawn
- 2012-06-19 RU RU2014101626/04A patent/RU2014101626A/ru not_active Application Discontinuation
- 2012-06-19 US US14/127,027 patent/US9006270B2/en not_active Expired - Fee Related
- 2012-06-19 CA CA2839621A patent/CA2839621A1/en not_active Abandoned
- 2012-06-19 BR BR112013032687A patent/BR112013032687A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140033432A (ko) | 2014-03-18 |
| CA2839621A1 (en) | 2012-12-27 |
| US20140171470A1 (en) | 2014-06-19 |
| WO2012175522A1 (en) | 2012-12-27 |
| RU2014101626A (ru) | 2015-07-27 |
| JP2014517049A (ja) | 2014-07-17 |
| BR112013032687A2 (pt) | 2016-08-30 |
| MX2013014887A (es) | 2014-02-17 |
| CN103619840B (zh) | 2016-01-20 |
| AU2012274141A1 (en) | 2013-12-12 |
| US9006270B2 (en) | 2015-04-14 |
| EP2723733A1 (en) | 2014-04-30 |
| CN103619840A (zh) | 2014-03-05 |
| AU2012274141B2 (en) | 2015-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ716487A (en) | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide | |
| ZA201201791B (en) | Method for the preparation of 2,5-furandicarboxylic acid and esters thereof | |
| ZA201201974B (en) | Method for the preparation of 2,5-furandicarboxylic acid and for the prepartion of the dialkyl ester of 2,5-furandicarboxylic acid | |
| PH12014502605A1 (en) | Uracyl spirooxetane nucleosides | |
| MY163394A (en) | Substituted aminobutyric derivates as neprilysin inhibitors | |
| NZ704662A (en) | Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid | |
| TN2012000465A1 (en) | Derivatives of 1-amino-2-cyclopropylethylboronic acid | |
| MX370852B (es) | Sal (es) de dimetil-amida del ácido 7-ciclopentil-2- (5-piperazin-1-il-piridin-2-il-amino) -7h-pirrolo- [2, 3-d]-pirimidin-6-carboxílico y procesos para su elaboración. | |
| EA020703B9 (ru) | Пиразолохиназолины | |
| SG10201805198TA (en) | 18f - fluciclovine compositions in citrate buffers | |
| IN2014CN03597A (enExample) | ||
| MX2015004947A (es) | Sistema cristalino multicomponente que comprende nilotinib y formadores de cocristal seleccionados. | |
| PH12017500089A1 (en) | Aldosterone synthase inhibitors | |
| MX2016002612A (es) | Forma polimorfica del derivado de pirrol y su intermedio. | |
| IN2015DN01151A (enExample) | ||
| PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
| PL2429507T3 (pl) | Kompozycja farmaceutyczna wolna od fosforanów do leczenia jaskry | |
| MX2012008413A (es) | Composicion novedosa de retigabina. | |
| CA2894715C (en) | Diazole amides | |
| IN2013DN02555A (enExample) | ||
| SI2532651T1 (sl) | Postopek sinteze in kristalinična oblika 4-(3-(cis-heksahidrociklopenta(c)pirol-2(1H)-il)propoksi) benzamid hidroklorida ter njegova prosta baza, pa tudi farmacevtski sestavki, ki ju vsebujejo | |
| IN2013MN00811A (enExample) | ||
| PH12013500945A1 (en) | Crystalline forms of an alkoxymidazol-1-ylmethyl-biphenyl carboxylic acid | |
| JO2851B1 (en) | 3-benzofuranil-indole-2-one-3-substituted acetamidopiprazine derivatives, preparations thereof and therapeutic use thereof. | |
| WO2013101719A3 (en) | Amooranin compounds and analogs thereof and related methods of use |